This review highlights the evidence to support the cardiovascular benefits provided by omega-3 fatty acids. For those with known coronary artery disease (CAD) the target DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) consumption level is approximately 1g/d and at least 500mg/d for those without disease.
Patients with hypertriglyceridaemia may benefit from treatment with 3-4g/d of DHA and EPA, a dosage that lowers triglyceride levels by 20-50%. Combination therapy with omega-3 fatty acids and a statin is a safe and effective way to improve lipid levels and cardiovascular prognosis beyong the benefits provided by statin therapy alone.
With new technologies, blood DHA and EPA levels can now be used to identify patients with deficient levels and to indivualise therapeutic recommendations. Click here to read more about this exciting new technology.